US4687765A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and composition for thrombolytic treatment
Assignee: Choay SA
•
Filing: 1985-07-30
•
Granted: 1987-08-18
•
Expires: 2005-07-30
Abstract
Abstract The invention relates to a method and composition for thrombolytic treatment. It comprises administering to thrombosis-afflicted patients a low molecular weight heparin in an amount effective to cause lysis of thrombi in vivo.
Inventors
- 👤 Edmond G. Vairel
- 👤 Huguette Brouty-Boye
- 👤 Francis Toulemonde
- 👤 Christian Doutremepuich
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 19:00
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
20 words
A method for the lysis of blood-thrombus comprising administering LMW heparin in an amount effective to exert thrombolysis in vivo.
Claim 2
Independent Claim
20 words
A method for the lysis of blood-thrombus comprising administering LMW heparin in an amount effective to exert thrombolysis in vivo.
Claim 3
Dependent Claim
21 words
The method of claim 1 wherein essential constituents of said LMW heparin have molecular weights ranging from about 2000 to 8000.
Claim 4
Dependent Claim
27 words
The method of claim 2 wherein said LMW heparin has a Yin-Wessler titer and a USP titer which are respectively in a ratio of at least 3.
Claim 5
Dependent Claim
15 words
The method of claim 3 wherein said USP titer is not less than 10 IU/mg.
Claim 6
Dependent Claim
22 words
The method of claim 4 wherein said Y W titer and USP titer are in a ratio ranging from 4 to 30.
Claim 7
Dependent Claim
14 words
The method of claim 3 wherein said USP titer is not less than 40/mg.
Claim 8
Dependent Claim
21 words
The method of claim 6 wherein said YW titer and USP titer are in a ratio ranging from 4 to 30.
Claim 9
Dependent Claim
22 words
The method of claim 3 wherein said LMW heparin is administered subcutaneously at dosages ranging from 25,000 to 100,000 AXa per day.
Claim 10
Dependent Claim
12 words
The method of claim 1 wherein said LMW heparin is administered intraparenterally.
Claim 11
Dependent Claim
12 words
The method of claim 1 wherein said LMW heparin is administered subcutaneously.
Claim 12
Independent Claim
26 words
A method for the lysis of blood-thrombus in vivo which comprises administering LMW heparin in an amount effective to cause lysis of insoluble fibrin in vivo.
Claim 13
Independent Claim
26 words
A method for the lysis of blood-thrombus in vivo which comprises administering LMW heparin in an amount effective to cause lysis of insoluble fibrin in vivo.
Claim 14
Independent Claim
30 words
A method for the lysis of blood-thrombus comprising administering LMW heparin in an amount effective to cause lysis of insoluble fibrin in vivo and causing said lysis of insoluble fibrin.
Claim 15
Independent Claim
30 words
A method for the lysis of blood-thrombus comprising administering LMW heparin in an amount effective to cause lysis of insoluble fibrin in vivo and causing said lysis of insoluble fibrin.
Claim 16
Dependent Claim
14 words
The method of claim 12 wherein the LMW heparin is derived from natural heparin.
Claim 17
Dependent Claim
16 words
The method of claim 12 wherein the lysis of insoluble fibrin is caused without creating hemmorhage.
Claim 18
Dependent Claim
16 words
The method of claim 12 wherein a therapeutically effective amount of LMW heparin is administered repeatedly.
Claim 19
Independent Claim
42 words
A method for the lysis of a pre-formed blood-thrombus in vivo which comprises administering LMW heparin to a patient having the pre-formed blood-thrombus in an amount effective to cause lysis of the pre-formed blood-thrombus and causing the lysis of the pre-formed blood-thrombus.
Claim 20
Independent Claim
42 words
A method for the lysis of a pre-formed blood-thrombus in vivo which comprises administering LMW heparin to a patient having the pre-formed blood-thrombus in an amount effective to cause lysis of the pre-formed blood-thrombus and causing the lysis of the pre-formed blood-thrombus.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-08-17 | 1991-02-16 | 1991-08-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-08-17 | 1995-02-16 | 1995-08-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-08-17 | 1999-02-16 | 1999-08-18 | $7700.00 | Window Closed / Lapsed |